​

​

CELLASTRA INC.

11/18/2024

Cellastra Appoints Emma Ye to the Executive Team

​Young Scientist and Entrepreneur promoted to Scientific Adviser, Communications

​

San Francisco, CA, November 18, 2024. Cellastra Inc. (Cellastra, a developer of gene therapy assets, announced today that Emma Ye, a young scientist and entrepreneur, has joined the Executive Team of the company, "We are excited to add Emma to our team to help guide the company into new areas of endless possibilities. She is also an excellent communicator, who can present complex issues with brilliance and clarity," says Karl Mettinger, MD, PhD, Chairman and CEO of Cellastra.  LINK

​

​CELLASTRA INC.

02/06/2024

Cellastra Receives US Patent for Recombinant Gene Vectors Encoded to Regulate Endogenous Production of Anti-Scarring/Adhesion Lactoferrin Biomolecules.

​​​​​​

San Francisco, CA, February 06, 2024. Cellastra Inc. (Cellastra (or “the Company”), a developer of novel gene therapy assets, announced today, that the company has been granted US Patent No. 11,891,429, entitled “Methods for regulating endogenous production of lactoferrin and sub-peptides thereof. ” The patent claims describe a recombinant virus vector (RVV) comprising a nucleotide sequence encoding a human lactoferrin protein or a sub-peptide thereof.  LINK 

​​​

CELLASTRA INC.

12/26/2023

​Cellastra appoints Brad  Thompson

to Chair, Scientific Advisory Board (SAB),

and Karl Mettinger to Chair (Interim),

Board of Directors.  LINK